Cyprotex
David Cerny has extensive experience in business development and marketing within the pharmaceutical and biotechnology industries. David has held various leadership positions in different companies, focusing on building business relationships and driving growth. David has a strong educational background with an MBA in International Business and a BA in Biology. David's expertise includes negotiation, strategic collaboration, market research, and forecasting.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology